Are sigma receptor modulators a weapon against multiple sclerosis disease?

2017 ◽  
Vol 9 (17) ◽  
pp. 2029-2051 ◽  
Author(s):  
Simona Collina ◽  
Marta Rui ◽  
Silvia Stotani ◽  
Emanuele Bignardi ◽  
Daniela Rossi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Sigma Receptor ◽  
Multiple Sclerosis Disease ◽  
Receptor Modulators

scholarly journals Leveraging electronic health records data to predict multiple sclerosis disease activity

2021 ◽  
Vol 8 (4) ◽  
pp. 800-810
Author(s):  
Yuri Ahuja ◽  
Nicole Kim ◽  
Liang Liang ◽  
Tianrun Cai ◽  
Kumar Dahal ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Electronic Health Records ◽  
Disease Activity ◽  
Health Records ◽  
Multiple Sclerosis Disease ◽  
Electronic Health

PATU11 IL2RA and CD226 genotypes influence multiple sclerosis disease outcome

2010 ◽  
Vol 81 (11) ◽  
pp. e27-e27
Author(s):  
T. Mihalova ◽  
M. Ban ◽  
A. Baker ◽  
R. Abraham ◽  
R. Strange ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Outcome ◽  
Multiple Sclerosis Disease

Adherence of Adolescents to Multiple Sclerosis Disease-Modifying Therapy

2009 ◽  
Vol 41 (2) ◽  
pp. 119-123 ◽  
Author(s):  
Jennifer E. Thannhauser ◽  
Jean K. Mah ◽  
Luanne M. Metz
Keyword(s):  
Multiple Sclerosis ◽  
Disease Modifying Therapy ◽  
Multiple Sclerosis Disease ◽  
Disease Modifying

scholarly journals Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment

2017 ◽  
Vol 24 (4) ◽  
pp. 472-480 ◽  
Author(s):  
Cyra E Leurs ◽  
Petar Podlesniy ◽  
Ramon Trullas ◽  
Lisanne Balk ◽  
Martijn D Steenwijk ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Disease Progression ◽  
Progressive Multiple Sclerosis ◽  
Neurologic Disease ◽  
Brain Volumes ◽  
Multiple Sclerosis Disease ◽  
Relapsing Remitting ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Digital Polymerase Chain Reaction

Background: Mitochondrial dysfunction is increasingly recognized as an important feature of multiple sclerosis (MS) pathology and may be relevant for clinical disease progression. However, it is unknown whether mitochondrial DNA (mtDNA) levels in the cerebrospinal fluid (CSF) associate with disease progression and therapeutic response. Objectives: To evaluate whether CSF concentrations of mtDNA in MS patients can serve as a marker of ongoing neuropathology and may be helpful to differentiate between MS disease subtypes. To explore the effect of disease-modifying therapies on mtDNA levels in the CSF. Methods: CSF mtDNA was measured using a digital polymerase chain reaction (PCR) CSF mtDNA in two independent MS cohorts. The cohorts included 92 relapsing-remitting multiple sclerosis (RRMS) patients, 40 progressive multiple sclerosis (PMS) patients (27 secondary progressive and 13 primary progressive), 50 various neurologic disease controls, and 5 healthy controls. Results: Patients with PMS showed a significant increase in CSF mtDNA compared to non-inflammatory neurologic disease controls. Patients with higher T2 lesion volumes and lower normalized brain volumes showed increased concentration of mtDNA. Patients treated with fingolimod had significantly lower mtDNA copy levels at follow-up compared to baseline. Conclusion: Our results showed a non-specific elevation of concentration of mtDNA in PMS patients. mtDNA concentrations respond to fingolimod and may be used to monitor biological effect of this treatment.

scholarly journals The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic

2020 ◽  
Vol 43 ◽  
pp. 102174 ◽  
Author(s):  
David Baker ◽  
Sandra Amor ◽  
Angray S. Kang ◽  
Klaus Schmierer ◽  
Gavin Giovannoni
Keyword(s):  
Multiple Sclerosis ◽  
Multiple Sclerosis Disease ◽  
Disease Modifying

scholarly journals 60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments

2020 ◽  
Vol 11 ◽  
Author(s):  
Marco Kaufmann ◽  
Milo Alan Puhan ◽  
Anke Salmen ◽  
Christian P. Kamm ◽  
Zina-Mary Manjaly ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Burden ◽  
Multiple Sclerosis Disease
Sign in / Sign up

Export Citation Format

Share Document